Here's Why This Laggard in the Coronavirus Vaccine Race Could Still Win
Novavax (NASDAQ: NVAX) isn't the closest company to the finish line of the coronavirus vaccine race. While some rivals expect initial phase 3 data this month -- competitors Moderna (NASDAQ: MRNA) and Pfizer (NYSE: PFE) expect to generate data by the end of November and to be ready to file for Emergency Use Authorizations (EUAs) soon afterward -- we'll have to wait until the first quarter of 2021 for Novavax's interim readout.
But being a few steps behind right now doesn't mean that Novavax won't eventually win the race. In fact, this company has something that no other coronavirus vaccine developer has: plans to explore a combined flu/COVID-19 vaccine. And that's why it may be worth waiting for what Novavax has to offer. Let's take a closer look.
Image source: Getty Images.
Source Fool.com
